Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $326 | $85 | $40 | $101 |
| - Cash | $9 | $13 | $13 | $63 |
| + Debt | $1 | $1 | $3 | $4 |
| Enterprise Value | $319 | $73 | $29 | $41 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$27 | -$23 | -$32 | -$38 |
| % Margin | – | – | – | – |
| Net Income | -$62 | -$27 | -$41 | -$43 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.02 | -0.563 | -0.89 | -1.03 |
| % Growth | -81.2% | 36.8% | 13.6% | – |
| Operating Cash Flow | -$25 | -$24 | -$27 | -$37 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$25 | -$24 | -$27 | -$37 |